OrganiGram Holdings, Inc.

September 02, 2014 08:00 ET

OrganiGram Passes Product Testing and Ships Medical Marijuana to Customers

MONCTON, NEW BRUNSWICK--(Marketwired - Sept. 2, 2014) - OrganiGram Holdings, Inc. (TSX VENTURE:OGI)(PINKSHEETS:OGRMF) (the "Company") is pleased to announce that it has shipped its first orders of medical marijuana to customers.

The product being shipped was sent to RPC Laboratory to undergo product testing as per Health Canada guidelines. The Company has received the results of said testing that confirm the product to be in conformance with the Health Canada Marihuana for Medical Purposes Regulations (MMPR).

CEO Denis Arsenault states, "We are extremely pleased to have passed testing and shipped product to our first customers. The fact that we were able to produce product that passed testing without the process of irradiation ("cold pasteurization"), confirms the high quality of our team, facility and validated the benefits of our Organic growing process."

About OrganiGram Holdings, Inc.

Organigram Holdings Inc. is a TSX Venture Exchange listed company who's wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.

Please visit for more information.

On Behalf of the Board of Directors of Organigram,

Denis Arsenault, President & CEO

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • OrganiGram Holdings, Inc.
    Brett Allan
    Director of Investor Relations
    (416) 907-4148